Orion Portfolio Solutions LLC Has $537,000 Holdings in Organon & Co. (NYSE:OGN)

Orion Portfolio Solutions LLC raised its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 237.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,025 shares of the company's stock after buying an additional 25,365 shares during the period. Orion Portfolio Solutions LLC's holdings in Organon & Co. were worth $537,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of OGN. Horizon Bancorp Inc. IN lifted its position in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after buying an additional 1,585 shares in the last quarter. Millstone Evans Group LLC bought a new position in shares of Organon & Co. in the fourth quarter worth about $29,000. Larson Financial Group LLC lifted its position in shares of Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after purchasing an additional 1,734 shares in the last quarter. Riverview Trust Co grew its stake in shares of Organon & Co. by 117.7% during the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company's stock valued at $36,000 after purchasing an additional 1,292 shares during the last quarter. Finally, Versant Capital Management Inc increased its holdings in shares of Organon & Co. by 92.2% in the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock valued at $41,000 after purchasing an additional 1,324 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have issued reports on OGN shares. Morgan Stanley reduced their price objective on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a report on Wednesday. Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, TD Cowen upgraded Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Organon & Co. currently has an average rating of "Hold" and an average price target of $20.60.

Organon & Co. Trading Down 2.3 %

Shares of Organon & Co. stock traded down $0.27 on Friday, hitting $11.17. 5,055,884 shares of the company's stock traded hands, compared to its average volume of 2,651,096. The firm's 50-day moving average price is $14.64 and its two-hundred day moving average price is $15.67. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The stock has a market capitalization of $2.88 billion, a PE ratio of 3.35, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. Organon & Co. has a one year low of $10.94 and a one year high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. On average, research analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 10.03%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s payout ratio is 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.